Search

Find exactly what you’re looking for.
Search

Service
Showing 21-30 of 30 results

Adam Cantor brings more than 25 years of legal experience to his new role as a partner in Saul Ewing’s Employee Benefits and Executive Compensation Practice, including advising clients on a wide array of executive and equity compensation, deferred compensation, and employee benefits matters. He also...

Saul Ewing attorneys hosted this fast-paced webinar, providing a list of things you need to know to develop your checklist for legal issues in 2023, from employment, corporate governance, cybersecurity and privacy, intellectual property to tax. Attorneys with specialized knowledge in these areas...

Opportunity Zones offer potential benefits for your clients, but it's crucial to distinguish between good and bad investments. Delve into the intricacies of the Opportunity Zone program, compliance and reporting obligations involved in maintaining these investments, and tax benefits that are...

Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...

(Washington, DC, July 21, 2021) – Earl Adams, Jr., co-chair of the firm’s Regulatory, Compliance and Government practice, and Managing Partner of the firm’s Washington, D.C. office, has been appointed by President Biden to serve as Chief Counsel to the Federal Motor Carrier Safety Administration (...

Saul Ewing LLP, a full-service law firm with attorneys in 16 offices, today announced that 59 attorneys from the Firm received the distinguished honor of being recognized for legal excellence and client service by Chambers USA 2022. Several of the Firm’s practice areas also earned high rankings...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us